Last 115.30 INR
Change Today -2.30 / -1.96%
Volume 12.0
KD On Other Exchanges
Symbol
Exchange
Mumbai
As of 2:14 AM 02/28/15 All times are local (Market data is delayed by at least 15 minutes).

kabra drugs ltd (KD) Snapshot

Open
115.30
Previous Close
117.60
Day High
115.30
Day Low
115.30
52 Week High
02/6/15 - 160.70
52 Week Low
06/30/14 - 5.51
Market Cap
506.1M
Average Volume 10 Days
176.9
EPS TTM
--
Shares Outstanding
4.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KABRA DRUGS LTD (KD)

Related News

No related news articles were found.

kabra drugs ltd (KD) Related Businessweek News

No Related Businessweek News Found

kabra drugs ltd (KD) Details

Kabra Drugs Limited engages in the manufacture and sale of drugs in India. The company offers ether, derivative, and pharmaceutical formulations. It manufactures ether derivatives, which include diethyl and solvent ethers, ethyl chloride sprays, and surgical products; liquid and dry injections, softgelatine capsules, and ethical based products; and a range of disinfectants, such as hand wash, hand sanitizer, and antimicrobial gels. The company also produces injectables for veterinary purposes. In addition, it provides liquids and eye/ear drops. The company also supplies its products to the Ministry Of Defense. Kabra Drugs Limited was incorporated in 1989 and is based in Indore, India.

Founded in 1989

kabra drugs ltd (KD) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kabra drugs ltd (KD) Key Developments

Kabra Drugs Limited expected to report Q3 2015 results on February 27, 2015. This event was calculated by Capital IQ (Created on February 21, 2015).

Kabra Drugs Limited expected to report Q3 2015 results on February 27, 2015. This event was calculated by Capital IQ (Created on February 21, 2015).

Kabra Drugs Limited Announces Unaudited Standalone Earnings Results for Second Quarter and Six Months Ended Sept. 30, 2014

Kabra Drugs Limited announced unaudited standalone earnings results for second quarter and six months ended Sept. 30, 2014. For the quarter, the company reported net sales/income from operations of INR 17.44 million, profit from operations before other income, interest and exceptional items of INR 0.734 million, profit from ordinary activities before tax of INR 0.734 million, net profit of INR 0.734 million or INR 0.17 per basic and diluted share compared to the net sales/income from operations of INR 49.843 million, profit from operations before other income, interest and exceptional items of INR 1.018 million, profit from ordinary activities before tax of INR 1.018 million, net profit of INR 1.018 million or INR 0.07 per basic and diluted share for the same quarter a year ago. For the year to date, the company reported net sales/income from operations of INR 38.988 million, profit from operations before other income, interest and exceptional items of INR 1.287 million, profit from ordinary activities before tax of INR 1.287 million, net profit of INR 0.734 million or INR 0.17 per basic and diluted share compared to the net sales/income from operations of INR 75.687 million, profit from operations before other income, interest and exceptional items of INR 1.716 million, profit from ordinary activities before tax of INR 1.716 million, net profit of INR 1.716 million or INR 0.07 per basic and diluted share for the same period a year ago.

Kabra Drugs Limited, Board Meeting, Nov 14, 2014

Kabra Drugs Limited, Board Meeting, Nov 14, 2014. Agenda: To consider unaudited standalone earnings results for second quarter and six months ended Sept. 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KD:IN 115.30 INR -2.30

KD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KD.
View Industry Companies
 

Industry Analysis

KD

Industry Average

Valuation KD Industry Range
Price/Earnings 100.0x
Price/Sales 6.7x
Price/Book -- Not Meaningful
Price/Cash Flow 171.5x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KABRA DRUGS LTD, please visit www.kabradrugslimited.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.